Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Giovanni Butturini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9172-4885; OpenAlex author ID A5101523581, A5108298322, A5111048273. Sources: ClinicalTrials.gov.

Their work

Papers
53 (first author 2, last author 9)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
246
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 1 paper · 2020: 5 papers · 2021: 4 papers · 2022: 2 papers · 2023: 7 papers · 2024: 8 papers · 2025: 6 papers · 2026: 5 papers, 1 trial

Papers 50 of 53

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  3. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … Co-author DOI 10.1016/j.esmoop.2026.106964↗
  4. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Last author DOI 10.3390/cancers18050830↗
  5. Gut Microbiome Compositional and Functional Signatures Associated with Chemotherapy Response in Pancreatic Ductal Adenocarcinoma: An Exploratory Cohort Study. Last author DOI 10.3390/metabo16100720↗
  6. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  7. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmogo.2025.100179↗
  10. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  11. Unconventional Treatments for Pancreatic Cancer: A Systematic Review. Last author DOI 10.3390/cancers17091437↗
  12. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  13. Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2024.09.010↗
  14. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  15. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  16. Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936). Co-author DOI 10.1177/03008916241291341↗
  17. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  18. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  19. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Last author DOI 10.3390/cancers16234106↗
  20. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  21. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2023.02.005↗
  22. Telemedicine and Pancreatic Cancer: A Systematic Review. Last author DOI 10.1089/tmj.2022.0140↗
  23. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  24. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  25. Co-design, co-learning, and co-production of an app for pancreatic cancer patients-the "Pancreas Plus" study protocol. Last author DOI 10.21037/mhealth-22-48↗
  26. Pancreatic Ductal Adenocarcinoma and Nutrition: Exploring the Role of Diet and Gut Health. Co-author DOI 10.3390/nu15204465↗
  27. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Last author DOI 10.1245/s10434-022-12385-4↗
  28. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients. Co-author DOI 10.3390/cells11213340↗
  29. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  30. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  31. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Co-author DOI 10.1097/sla.0000000000003717↗
  32. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  33. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  34. Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Co-author DOI 10.1016/j.dld.2020.07.027↗
  35. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  36. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
  37. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  38. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Regis… Co-author DOI 10.1038/s41395-018-0414-z↗
  39. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Co-author DOI 10.1007/s00464-018-6217-x↗
  40. Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air. Co-author DOI 10.1186/s12885-018-4452-0↗
  41. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Co-author DOI 10.1016/j.pan.2017.09.008↗
  42. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Co-author DOI 10.1177/1533034616649292↗
  43. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Last author DOI 10.1245/s10434-017-5885-4↗
  44. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. Co-author DOI 10.4103/eus.eus_67_17↗
  45. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2016.02.003↗
  46. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  47. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.085↗
  48. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. First author DOI 10.1159/000375323↗
  49. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Co-author DOI 10.1002/ijc.28765↗
  50. Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. Co-author DOI 10.1111/hpb.12073↗

Trials 1

  1. PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) Principal investigator NCT07422103↗

Closest collaborators

The 25 strongest of 246 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabella M. Frigerio · 23 shared papers, 2015–2026 · strength 3.15
  2. Roberto Salvia · 20 shared papers, 2011–2026 · strength 2.04
  3. Alessandro Giardino · 13 shared papers, 2017–2026 · strength 1.81
  4. Claudio Bassi · 20 shared papers, 2011–2024 · strength 1.50
  5. Erica Pizzocaro · 6 shared papers, 2023–2026 · strength 1.46
  6. Paolo Regi · 11 shared papers, 2011–2026 · strength 1.22
  7. Massimo Falconi · 12 shared papers, 2013–2026 · strength 1.20
  8. Roberto Girelli · 10 shared papers, 2016–2026 · strength 1.14
  9. Filippo Scopelliti · 9 shared papers, 2017–2026 · strength 1.10
  10. Salvatore Paiella · 12 shared papers, 2015–2026 · strength 1.04
  11. Giuseppe Malleo · 11 shared papers, 2011–2025 · strength 1.01
  12. Marc G. Besselink · 8 shared papers, 2020–2025 · strength 0.88
  13. Marzia Tripepi · 4 shared papers, 2023–2024 · strength 0.82
  14. Alessandro Zerbi · 7 shared papers, 2019–2024 · strength 0.76
  15. Simona Casalino · 4 shared papers, 2020–2026 · strength 0.73
  16. Davide Melisi · 4 shared papers, 2020–2026 · strength 0.73
  17. Thilo Hackert · 7 shared papers, 2016–2025 · strength 0.72
  18. Mirko D’Onofrio · 9 shared papers, 2011–2024 · strength 0.64
  19. Tobias Keck · 6 shared papers, 2020–2025 · strength 0.64
  20. Alessandro Esposito · 5 shared papers, 2020–2024 · strength 0.60
  21. Mohammad Abu Hilal · 6 shared papers, 2020–2024 · strength 0.60
  22. Gaya Spolverato · 3 shared papers, 2023–2024 · strength 0.55
  23. Quoc Riccardo Bao · 3 shared papers, 2023–2024 · strength 0.55
  24. Bas Groot Koerkamp · 5 shared papers, 2020–2025 · strength 0.55
  25. Riccardo Casadei · 5 shared papers, 2020–2024 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.